Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. RARE Peers
See (RARE) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RARE | $35.44 | -5.11% | 3.35B | -6.08 | -$5.83 | N/A |
| VRTX | $435.32 | -2.65% | 111.79B | -114.56 | -$3.80 | N/A |
| REGN | $604.64 | -1.65% | 64.18B | 15.38 | $39.31 | +0.29% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $292.58 | +0.31% | 38.15B | -133.60 | -$2.19 | N/A |
| ARGX | $584.95 | +1.15% | 35.72B | 45.81 | $12.77 | N/A |
| BNTX | $99.09 | -2.59% | 23.82B | -27.83 | -$3.56 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| SMMT | $25.41 | +4.18% | 18.74B | -74.74 | -$0.34 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
Stock Comparison
RARE vs VRTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, VRTX has a market cap of 111.79B. Regarding current trading prices, RARE is priced at $35.44, while VRTX trades at $435.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas VRTX's P/E ratio is -114.56. In terms of profitability, RARE's ROE is -1.86%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, RARE is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs REGN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, REGN has a market cap of 64.18B. Regarding current trading prices, RARE is priced at $35.44, while REGN trades at $604.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas REGN's P/E ratio is 15.38. In terms of profitability, RARE's ROE is -1.86%, compared to REGN's ROE of +0.15%. Regarding short-term risk, RARE is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs SGEN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, RARE is priced at $35.44, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SGEN's P/E ratio is -57.19. In terms of profitability, RARE's ROE is -1.86%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, RARE is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ALNY Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ALNY has a market cap of 38.15B. Regarding current trading prices, RARE is priced at $35.44, while ALNY trades at $292.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ALNY's P/E ratio is -133.60. In terms of profitability, RARE's ROE is -1.86%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, RARE is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ARGX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ARGX has a market cap of 35.72B. Regarding current trading prices, RARE is priced at $35.44, while ARGX trades at $584.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ARGX's P/E ratio is 45.81. In terms of profitability, RARE's ROE is -1.86%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, RARE is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BNTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BNTX has a market cap of 23.82B. Regarding current trading prices, RARE is priced at $35.44, while BNTX trades at $99.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BNTX's P/E ratio is -27.83. In terms of profitability, RARE's ROE is -1.86%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, RARE is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BGNE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, RARE is priced at $35.44, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BGNE's P/E ratio is -22.55. In terms of profitability, RARE's ROE is -1.86%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, RARE is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs SMMT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SMMT has a market cap of 18.74B. Regarding current trading prices, RARE is priced at $35.44, while SMMT trades at $25.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SMMT's P/E ratio is -74.74. In terms of profitability, RARE's ROE is -1.86%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, RARE is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs DNA-WT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, RARE is priced at $35.44, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, RARE's ROE is -1.86%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, RARE is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs RPRX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RPRX has a market cap of 18.46B. Regarding current trading prices, RARE is priced at $35.44, while RPRX trades at $32.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RPRX's P/E ratio is 13.40. In terms of profitability, RARE's ROE is -1.86%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, RARE is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs UTHR Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, UTHR has a market cap of 13.97B. Regarding current trading prices, RARE is priced at $35.44, while UTHR trades at $309.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas UTHR's P/E ratio is 12.57. In terms of profitability, RARE's ROE is -1.86%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs GMAB Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, GMAB has a market cap of 12.66B. Regarding current trading prices, RARE is priced at $35.44, while GMAB trades at $20.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas GMAB's P/E ratio is 12.07. In terms of profitability, RARE's ROE is -1.86%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, RARE is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs KRTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, RARE is priced at $35.44, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas KRTX's P/E ratio is -28.09. In terms of profitability, RARE's ROE is -1.86%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, RARE is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs INCY Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, INCY has a market cap of 12.54B. Regarding current trading prices, RARE is priced at $35.44, while INCY trades at $64.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas INCY's P/E ratio is 323.90. In terms of profitability, RARE's ROE is -1.86%, compared to INCY's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs EXEL Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, EXEL has a market cap of 11.92B. Regarding current trading prices, RARE is priced at $35.44, while EXEL trades at $43.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas EXEL's P/E ratio is 19.96. In terms of profitability, RARE's ROE is -1.86%, compared to EXEL's ROE of +0.29%. Regarding short-term risk, RARE is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BMRN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BMRN has a market cap of 11.22B. Regarding current trading prices, RARE is priced at $35.44, while BMRN trades at $58.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BMRN's P/E ratio is 21.66. In terms of profitability, RARE's ROE is -1.86%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, RARE is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MRNA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MRNA has a market cap of 9.98B. Regarding current trading prices, RARE is priced at $35.44, while MRNA trades at $25.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MRNA's P/E ratio is -2.96. In terms of profitability, RARE's ROE is -1.86%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, RARE is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs RXDX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, RARE is priced at $35.44, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RXDX's P/E ratio is -56.47. In terms of profitability, RARE's ROE is -1.86%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ASND Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ASND has a market cap of 9.55B. Regarding current trading prices, RARE is priced at $35.44, while ASND trades at $158.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ASND's P/E ratio is -24.32. In terms of profitability, RARE's ROE is -1.86%, compared to ASND's ROE of +1.91%. Regarding short-term risk, RARE is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs IMGN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, RARE is priced at $35.44, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas IMGN's P/E ratio is -111.55. In terms of profitability, RARE's ROE is -1.86%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, RARE is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CERE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, RARE is priced at $35.44, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CERE's P/E ratio is -16.47. In terms of profitability, RARE's ROE is -1.86%, compared to CERE's ROE of -0.99%. Regarding short-term risk, RARE is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CORT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CORT has a market cap of 8.04B. Regarding current trading prices, RARE is priced at $35.44, while CORT trades at $75.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CORT's P/E ratio is 65.91. In terms of profitability, RARE's ROE is -1.86%, compared to CORT's ROE of +0.20%. Regarding short-term risk, RARE is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ROIVW Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, RARE is priced at $35.44, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, RARE's ROE is -1.86%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, RARE is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs ROIV Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ROIV has a market cap of 7.78B. Regarding current trading prices, RARE is priced at $35.44, while ROIV trades at $10.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ROIV's P/E ratio is -10.91. In terms of profitability, RARE's ROE is -1.86%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, RARE is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs TECH Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, TECH has a market cap of 7.31B. Regarding current trading prices, RARE is priced at $35.44, while TECH trades at $46.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas TECH's P/E ratio is 56.22. In terms of profitability, RARE's ROE is -1.86%, compared to TECH's ROE of +0.06%. Regarding short-term risk, RARE is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs RVMD Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RVMD has a market cap of 7.22B. Regarding current trading prices, RARE is priced at $35.44, while RVMD trades at $38.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RVMD's P/E ratio is -9.66. In terms of profitability, RARE's ROE is -1.86%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, RARE is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs JAZZ Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, JAZZ has a market cap of 6.67B. Regarding current trading prices, RARE is priced at $35.44, while JAZZ trades at $108.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas JAZZ's P/E ratio is 14.71. In terms of profitability, RARE's ROE is -1.86%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, RARE is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs HALO Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, HALO has a market cap of 6.65B. Regarding current trading prices, RARE is priced at $35.44, while HALO trades at $53.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas HALO's P/E ratio is 15.72. In terms of profitability, RARE's ROE is -1.86%, compared to HALO's ROE of +1.22%. Regarding short-term risk, RARE is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs RETA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, RARE is priced at $35.44, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RETA's P/E ratio is -66.29. In terms of profitability, RARE's ROE is -1.86%, compared to RETA's ROE of +0.47%. Regarding short-term risk, RARE is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BPMC Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BPMC has a market cap of 6.56B. Regarding current trading prices, RARE is priced at $35.44, while BPMC trades at $101.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BPMC's P/E ratio is -40.44. In terms of profitability, RARE's ROE is -1.86%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, RARE is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs VRNA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, VRNA has a market cap of 6.30B. Regarding current trading prices, RARE is priced at $35.44, while VRNA trades at $74.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas VRNA's P/E ratio is -37.04. In terms of profitability, RARE's ROE is -1.86%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, RARE is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BBIO Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BBIO has a market cap of 6.24B. Regarding current trading prices, RARE is priced at $35.44, while BBIO trades at $32.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BBIO's P/E ratio is -11.40. In terms of profitability, RARE's ROE is -1.86%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, RARE is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MDGL Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MDGL has a market cap of 6.16B. Regarding current trading prices, RARE is priced at $35.44, while MDGL trades at $277.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MDGL's P/E ratio is -15.55. In terms of profitability, RARE's ROE is -1.86%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, RARE is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs TLX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, TLX has a market cap of 5.56B. Regarding current trading prices, RARE is priced at $35.44, while TLX trades at $16.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas TLX's P/E ratio is 184.67. In terms of profitability, RARE's ROE is -1.86%, compared to TLX's ROE of +0.14%. Regarding short-term risk, RARE is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ABCM Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, RARE is priced at $35.44, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, RARE's ROE is -1.86%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, RARE is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ISEE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, RARE is priced at $35.44, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ISEE's P/E ratio is -22.44. In terms of profitability, RARE's ROE is -1.86%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, RARE is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs TGTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, TGTX has a market cap of 5.43B. Regarding current trading prices, RARE is priced at $35.44, while TGTX trades at $34.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas TGTX's P/E ratio is 136.80. In terms of profitability, RARE's ROE is -1.86%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, RARE is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs IONS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, IONS has a market cap of 5.33B. Regarding current trading prices, RARE is priced at $35.44, while IONS trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas IONS's P/E ratio is -11.20. In terms of profitability, RARE's ROE is -1.86%, compared to IONS's ROE of -0.00%. Regarding short-term risk, RARE is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs NUVL Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, NUVL has a market cap of 5.29B. Regarding current trading prices, RARE is priced at $35.44, while NUVL trades at $73.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas NUVL's P/E ratio is -16.67. In terms of profitability, RARE's ROE is -1.86%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs AXSM Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, AXSM has a market cap of 5.21B. Regarding current trading prices, RARE is priced at $35.44, while AXSM trades at $105.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas AXSM's P/E ratio is -18.30. In terms of profitability, RARE's ROE is -1.86%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, RARE is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ALKS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ALKS has a market cap of 5.03B. Regarding current trading prices, RARE is priced at $35.44, while ALKS trades at $30.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ALKS's P/E ratio is 14.54. In terms of profitability, RARE's ROE is -1.86%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, RARE is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ADMA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ADMA has a market cap of 4.80B. Regarding current trading prices, RARE is priced at $35.44, while ADMA trades at $20.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ADMA's P/E ratio is 23.95. In terms of profitability, RARE's ROE is -1.86%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, RARE is more volatile compared to ADMA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ALPN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, RARE is priced at $35.44, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ALPN's P/E ratio is -101.52. In terms of profitability, RARE's ROE is -1.86%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, RARE is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs PCVX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, PCVX has a market cap of 4.38B. Regarding current trading prices, RARE is priced at $35.44, while PCVX trades at $33.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas PCVX's P/E ratio is -8.51. In terms of profitability, RARE's ROE is -1.86%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, RARE is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs OPT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, RARE is priced at $35.44, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas OPT's P/E ratio is -1.52. In terms of profitability, RARE's ROE is -1.86%, compared to OPT's ROE of +2.60%. Regarding short-term risk, RARE is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MRTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, RARE is priced at $35.44, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MRTX's P/E ratio is -4.82. In terms of profitability, RARE's ROE is -1.86%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, RARE is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs RYTM Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RYTM has a market cap of 3.97B. Regarding current trading prices, RARE is priced at $35.44, while RYTM trades at $62.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RYTM's P/E ratio is -22.27. In terms of profitability, RARE's ROE is -1.86%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, RARE is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs SRPT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SRPT has a market cap of 3.94B. Regarding current trading prices, RARE is priced at $35.44, while SRPT trades at $40.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SRPT's P/E ratio is -15.17. In terms of profitability, RARE's ROE is -1.86%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, RARE is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs AKRO Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, AKRO has a market cap of 3.85B. Regarding current trading prices, RARE is priced at $35.44, while AKRO trades at $48.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas AKRO's P/E ratio is -12.89. In terms of profitability, RARE's ROE is -1.86%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, RARE is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs RYZB Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, RARE is priced at $35.44, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RYZB's P/E ratio is -57.86. In terms of profitability, RARE's ROE is -1.86%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, RARE is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CYTK Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CYTK has a market cap of 3.74B. Regarding current trading prices, RARE is priced at $35.44, while CYTK trades at $31.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CYTK's P/E ratio is -5.92. In terms of profitability, RARE's ROE is -1.86%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, RARE is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CBAY Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, RARE is priced at $35.44, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CBAY's P/E ratio is -32.81. In terms of profitability, RARE's ROE is -1.86%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, RARE is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs SLNO Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SLNO has a market cap of 3.69B. Regarding current trading prices, RARE is priced at $35.44, while SLNO trades at $73.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SLNO's P/E ratio is -15.46. In terms of profitability, RARE's ROE is -1.86%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, RARE is more volatile compared to SLNO. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs RNA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, RNA has a market cap of 3.69B. Regarding current trading prices, RARE is priced at $35.44, while RNA trades at $30.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas RNA's P/E ratio is -10.21. In terms of profitability, RARE's ROE is -1.86%, compared to RNA's ROE of -0.27%. Regarding short-term risk, RARE is more volatile compared to RNA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs PTCT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, PTCT has a market cap of 3.66B. Regarding current trading prices, RARE is priced at $35.44, while PTCT trades at $46.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas PTCT's P/E ratio is -9.77. In terms of profitability, RARE's ROE is -1.86%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, RARE is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs KRYS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, KRYS has a market cap of 3.66B. Regarding current trading prices, RARE is priced at $35.44, while KRYS trades at $126.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas KRYS's P/E ratio is 42.37. In terms of profitability, RARE's ROE is -1.86%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, RARE is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ACAD Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ACAD has a market cap of 3.66B. Regarding current trading prices, RARE is priced at $35.44, while ACAD trades at $21.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ACAD's P/E ratio is 15.95. In terms of profitability, RARE's ROE is -1.86%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, RARE is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs ACLX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ACLX has a market cap of 3.61B. Regarding current trading prices, RARE is priced at $35.44, while ACLX trades at $65.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ACLX's P/E ratio is -21.92. In terms of profitability, RARE's ROE is -1.86%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, RARE is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs SWTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SWTX has a market cap of 3.48B. Regarding current trading prices, RARE is priced at $35.44, while SWTX trades at $46.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SWTX's P/E ratio is -13.55. In terms of profitability, RARE's ROE is -1.86%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, RARE is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CRSP Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CRSP has a market cap of 3.19B. Regarding current trading prices, RARE is priced at $35.44, while CRSP trades at $36.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CRSP's P/E ratio is -8.24. In terms of profitability, RARE's ROE is -1.86%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, RARE is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs VKTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, VKTX has a market cap of 3.06B. Regarding current trading prices, RARE is priced at $35.44, while VKTX trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas VKTX's P/E ratio is -23.49. In terms of profitability, RARE's ROE is -1.86%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, RARE is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs MTSR Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MTSR has a market cap of 3.01B. Regarding current trading prices, RARE is priced at $35.44, while MTSR trades at $28.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MTSR's P/E ratio is -11.34. In terms of profitability, RARE's ROE is -1.86%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, RARE is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs MRUS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MRUS has a market cap of 2.99B. Regarding current trading prices, RARE is priced at $35.44, while MRUS trades at $43.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MRUS's P/E ratio is -10.39. In terms of profitability, RARE's ROE is -1.86%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, RARE is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CPRX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CPRX has a market cap of 2.97B. Regarding current trading prices, RARE is priced at $35.44, while CPRX trades at $24.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CPRX's P/E ratio is 15.49. In terms of profitability, RARE's ROE is -1.86%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, RARE is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs SRRK Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, SRRK has a market cap of 2.92B. Regarding current trading prices, RARE is priced at $35.44, while SRRK trades at $30.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas SRRK's P/E ratio is -12.05. In terms of profitability, RARE's ROE is -1.86%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, RARE is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MORF Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, RARE is priced at $35.44, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MORF's P/E ratio is -14.88. In terms of profitability, RARE's ROE is -1.86%, compared to MORF's ROE of -0.27%. Regarding short-term risk, RARE is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MOR Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, RARE is priced at $35.44, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MOR's P/E ratio is -12.64. In terms of profitability, RARE's ROE is -1.86%, compared to MOR's ROE of +7.43%. Regarding short-term risk, RARE is more volatile compared to MOR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs PTGX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, PTGX has a market cap of 2.84B. Regarding current trading prices, RARE is priced at $35.44, while PTGX trades at $45.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas PTGX's P/E ratio is 58.74. In terms of profitability, RARE's ROE is -1.86%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, RARE is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CRNX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CRNX has a market cap of 2.81B. Regarding current trading prices, RARE is priced at $35.44, while CRNX trades at $29.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CRNX's P/E ratio is -7.88. In terms of profitability, RARE's ROE is -1.86%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, RARE is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs KDNY Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, RARE is priced at $35.44, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas KDNY's P/E ratio is -12.47. In terms of profitability, RARE's ROE is -1.86%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, RARE is more volatile compared to KDNY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MYOV Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, RARE is priced at $35.44, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MYOV's P/E ratio is -14.05. In terms of profitability, RARE's ROE is -1.86%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, RARE is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs LEGN Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, LEGN has a market cap of 2.61B. Regarding current trading prices, RARE is priced at $35.44, while LEGN trades at $28.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas LEGN's P/E ratio is -24.01. In terms of profitability, RARE's ROE is -1.86%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, RARE is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs IMVT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, IMVT has a market cap of 2.45B. Regarding current trading prices, RARE is priced at $35.44, while IMVT trades at $14.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas IMVT's P/E ratio is -5.50. In terms of profitability, RARE's ROE is -1.86%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, RARE is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MLTX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MLTX has a market cap of 2.45B. Regarding current trading prices, RARE is priced at $35.44, while MLTX trades at $38.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MLTX's P/E ratio is -21.53. In terms of profitability, RARE's ROE is -1.86%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, RARE is more volatile compared to MLTX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs APGE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, APGE has a market cap of 2.39B. Regarding current trading prices, RARE is priced at $35.44, while APGE trades at $40.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas APGE's P/E ratio is -11.13. In terms of profitability, RARE's ROE is -1.86%, compared to APGE's ROE of -0.19%. Regarding short-term risk, RARE is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs PRVB Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, RARE is priced at $35.44, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas PRVB's P/E ratio is -16.43. In terms of profitability, RARE's ROE is -1.86%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, RARE is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs LBPH Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, RARE is priced at $35.44, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas LBPH's P/E ratio is -26.66. In terms of profitability, RARE's ROE is -1.86%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, RARE is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs IBRX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, IBRX has a market cap of 2.34B. Regarding current trading prices, RARE is priced at $35.44, while IBRX trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas IBRX's P/E ratio is -4.65. In terms of profitability, RARE's ROE is -1.86%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, RARE is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs XENE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, XENE has a market cap of 2.34B. Regarding current trading prices, RARE is priced at $35.44, while XENE trades at $30.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas XENE's P/E ratio is -9.46. In terms of profitability, RARE's ROE is -1.86%, compared to XENE's ROE of -0.32%. Regarding short-term risk, RARE is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs DICE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, RARE is priced at $35.44, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas DICE's P/E ratio is -21.91. In terms of profitability, RARE's ROE is -1.86%, compared to DICE's ROE of +0.56%. Regarding short-term risk, RARE is more volatile compared to DICE. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs MIRM Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, MIRM has a market cap of 2.19B. Regarding current trading prices, RARE is priced at $35.44, while MIRM trades at $44.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas MIRM's P/E ratio is -25.32. In terms of profitability, RARE's ROE is -1.86%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, RARE is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs BLTE Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BLTE has a market cap of 2.19B. Regarding current trading prices, RARE is priced at $35.44, while BLTE trades at $67.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BLTE's P/E ratio is -49.48. In terms of profitability, RARE's ROE is -1.86%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, RARE is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs APLS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, APLS has a market cap of 2.19B. Regarding current trading prices, RARE is priced at $35.44, while APLS trades at $17.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas APLS's P/E ratio is -9.68. In terms of profitability, RARE's ROE is -1.86%, compared to APLS's ROE of -1.00%. Regarding short-term risk, RARE is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs AAPG Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, AAPG has a market cap of 2.18B. Regarding current trading prices, RARE is priced at $35.44, while AAPG trades at $25.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas AAPG's P/E ratio is -34.38. In terms of profitability, RARE's ROE is -1.86%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, RARE is more volatile compared to AAPG. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs VCYT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, VCYT has a market cap of 2.16B. Regarding current trading prices, RARE is priced at $35.44, while VCYT trades at $27.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas VCYT's P/E ratio is 65.69. In terms of profitability, RARE's ROE is -1.86%, compared to VCYT's ROE of +0.03%. Regarding short-term risk, RARE is more volatile compared to VCYT. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CALT Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, RARE is priced at $35.44, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CALT's P/E ratio is -22.73. In terms of profitability, RARE's ROE is -1.86%, compared to CALT's ROE of -2.10%. Regarding short-term risk, RARE is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs ARWR Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, ARWR has a market cap of 2.11B. Regarding current trading prices, RARE is priced at $35.44, while ARWR trades at $15.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas ARWR's P/E ratio is -12.35. In terms of profitability, RARE's ROE is -1.86%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, RARE is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs BCRX Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, BCRX has a market cap of 2.11B. Regarding current trading prices, RARE is priced at $35.44, while BCRX trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas BCRX's P/E ratio is -38.73. In terms of profitability, RARE's ROE is -1.86%, compared to BCRX's ROE of +0.11%. Regarding short-term risk, RARE is more volatile compared to BCRX. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs NAMS Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, NAMS has a market cap of 2.07B. Regarding current trading prices, RARE is priced at $35.44, while NAMS trades at $18.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas NAMS's P/E ratio is -10.03. In terms of profitability, RARE's ROE is -1.86%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, RARE is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs VCEL Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, VCEL has a market cap of 2.07B. Regarding current trading prices, RARE is priced at $35.44, while VCEL trades at $41.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas VCEL's P/E ratio is 205.35. In terms of profitability, RARE's ROE is -1.86%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, RARE is more volatile compared to VCEL. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs CGON Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, CGON has a market cap of 2.00B. Regarding current trading prices, RARE is priced at $35.44, while CGON trades at $26.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas CGON's P/E ratio is -17.48. In terms of profitability, RARE's ROE is -1.86%, compared to CGON's ROE of -0.11%. Regarding short-term risk, RARE is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs DNLI Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, DNLI has a market cap of 1.99B. Regarding current trading prices, RARE is priced at $35.44, while DNLI trades at $13.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas DNLI's P/E ratio is -5.13. In terms of profitability, RARE's ROE is -1.86%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, RARE is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs HRMY Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, HRMY has a market cap of 1.98B. Regarding current trading prices, RARE is priced at $35.44, while HRMY trades at $34.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas HRMY's P/E ratio is 13.17. In terms of profitability, RARE's ROE is -1.86%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, RARE is more volatile compared to HRMY. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs LGND Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, LGND has a market cap of 1.98B. Regarding current trading prices, RARE is priced at $35.44, while LGND trades at $102.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas LGND's P/E ratio is -14.05. In terms of profitability, RARE's ROE is -1.86%, compared to LGND's ROE of -0.16%. Regarding short-term risk, RARE is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs NAMSW Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, NAMSW has a market cap of 1.96B. Regarding current trading prices, RARE is priced at $35.44, while NAMSW trades at $8.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas NAMSW's P/E ratio is N/A. In terms of profitability, RARE's ROE is -1.86%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, RARE is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for RARE.
RARE vs KYMR Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, KYMR has a market cap of 1.96B. Regarding current trading prices, RARE is priced at $35.44, while KYMR trades at $30.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas KYMR's P/E ratio is -9.69. In terms of profitability, RARE's ROE is -1.86%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, RARE is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs FOLD Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, FOLD has a market cap of 1.95B. Regarding current trading prices, RARE is priced at $35.44, while FOLD trades at $6.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas FOLD's P/E ratio is -70.44. In terms of profitability, RARE's ROE is -1.86%, compared to FOLD's ROE of -0.17%. Regarding short-term risk, RARE is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs GLPG Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, GLPG has a market cap of 1.91B. Regarding current trading prices, RARE is priced at $35.44, while GLPG trades at $28.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas GLPG's P/E ratio is -9.50. In terms of profitability, RARE's ROE is -1.86%, compared to GLPG's ROE of -0.06%. Regarding short-term risk, RARE is more volatile compared to GLPG. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.
RARE vs KNSA Comparison
RARE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RARE stands at 3.35B. In comparison, KNSA has a market cap of 1.91B. Regarding current trading prices, RARE is priced at $35.44, while KNSA trades at $26.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RARE currently has a P/E ratio of -6.08, whereas KNSA's P/E ratio is -108.83. In terms of profitability, RARE's ROE is -1.86%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, RARE is more volatile compared to KNSA. This indicates potentially higher risk in terms of short-term price fluctuations for RARE.